Monique Dabbous

Economics, Econometrics and Finance · Social Sciences

8h-index294citations33works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Health Systems, Economic Evaluations, Quality of Life(19), Pharmaceutical Economics and Policy(19), Pharmaceutical industry and healthcare(5), Biomedical Ethics and Regulation(5), Biosimilars and Bioanalytical Methods(4)

Publications33 total

PCR90 Patient Voice and Patient Engagement in Value Assessment Frameworks and HTA Decision-Making for Gene Therapies
Value in Health·2024
The impact of amortization of gene therapies funding on the results and conclusions of CEMs and BIMs
Journal of Market Access & Health Policy·2023Open Access
HTA34 A Review of Real-World Evidence in Health Technology Assessment Decision-Making of Gene Therapies in the US, Canada, UK, EU4, and Japan
Value in Health·2023Open Access
HTA50 HTA Bodies Acceptance of Indirect Treatment Comparisons for Gene Therapies in US, England and Wales, France and Germany
Value in Health·2023Open Access
Amortization of gene replacement therapies: A health policy analysis exploring a mechanism for mitigating budget impact of high-cost treatments
Health Policy·2021· 15 cited
The Amortization of Funding Gene Therapies: Making the “Intangibles” Tangible for Patients
2021· 2 citedOpen Access
Use of Patient Preference Information in Benefit–Risk Assessment, Health Technology Assessment, and Pricing and Reimbursement Decisions: A Systematic Literature Review of Attempts and Initiatives
Frontiers in Medicine·2020· 31 citedOpen Access
Current state of developing advanced therapies for rare diseases in the European Union
Expert Opinion on Orphan Drugs·2020· 8 cited
Joint collaborations and future perspectives for gene therapies.
Cell and Gene Therapy Insights·2020
COVID-19: Why SOLIDARITY and DisCoVeRy trials may fail to bring informative and timely results
2020· 4 citedOpen Access
Rapid systematic review on clinical evidence of chloroquine and hydroxychloroquine in COVID-19: critical assessment and recommendation for future clinical trials
2020· 5 citedOpen Access
Regenerative medicine regulatory policies: A systematic review and international comparison
Health Policy·2020· 46 cited
Chinese Clinical Studies for Pharmacological Treatments of Coronavirus Disease 2019 (COVID-19)
Preprints.org·2020· 4 citedOpen Access
Chinese Guidelines Related to Novel Coronavirus Pneumonia
Preprints.org·2020· 8 citedOpen Access
Managed Entry Agreements: Policy Analysis From the European Perspective
Value in Health·2020· 100 cited
Chinese guidelines related to novel coronavirus pneumonia
Journal of Market Access & Health Policy·2020· 47 citedOpen Access
PNS365 THE ADDED VALUE OF USE OF PATIENT PREFERENCE STUDIES IN POLICY DECISION-MAKING: A LITERATURE REVIEW
Value in Health·2019Open Access
PND5 OVERCOMING MARKET ACCESS AND COMMERCIALIZATION CHALLENGES IN GENE THERAPIES FOR RARE CNS DISEASES: GENE THERAPY CLINICAL TRIALS FOR RARE CNS DISEASES LANDSCAPE
Value in Health·2019Open Access
Health Technology Assessment of Gene Therapies in Europe and the USA: Analysis and Future Considerations
Cell and Gene Therapy Insights·2019· 8 cited
The diversity in regenerative medicines regulations in Europe, USA and Japan
Cell and Gene Therapy Insights·2019· 2 cited
page 1 of 2Next →

Frequent Co-authors

Mondher Toumi(30), Lylia Chachoua(16), E. Hanna(9), C. François(7), Claude Dussart(7), Shuyao Liang(6), Ru Han(6), Leila Achour(6), Tingting Qiu(4), Eve Hanna(4), Tingting Qiu(4), Steven Simoens(3), Yitong Wang(3), Yitong Wang(3), Borisov Borislav(2), Jürgen Wasem(2), Lieven Annemans(2), Johann‐Matthias Graf von der Schulenburg(2), Oriol Solà-Morales(2), Daniel C. Malone(2)